Skip to content
value.today
Celularity Inc. logo

Celularity Inc.

CELU
$28 Mmarket cap on Oct 30, 2026-50.8% since Jan 2024
Compare
World rank
#23,327
Revenue
$27 M
For year ending December-2025
Net income
$-92 M
-345.5% margin
SEC filing
Employees
288
As on July 2022
value.today research

Celularity Inc. in brief

Celularity Inc. is a listed company in the Biotechnology industry, based in Florham Park, New Jersey, USA. Its market value was $28 M on 30 October 2026, which makes it the 23,327th largest listed company in the world and the 4,061st largest in the USA on this site. In the year to December 2025 it had sales of $27 M and a net loss of $92 M. It employs about 288 people and Robert J. Hariri is its chief executive. Its largest product and service lines by sales in 2025 were License Royalty and Other (30%). Its shares trade under the symbol CELU (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Celularity Inc.

Celularity is a Clinical Stage Biotechnology company developing targeting indications across cancer, immunologic, infectious and degenerative diseases. The company estimated annual revenue is currently 32.2 million USD. The headquarters is in USA.

Celularity Inc. timeline

4 events, 2018–2024
  1. 2018
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2019
  4. 🔔
    Initial public offering as GX Acquisition Corp.
    Final prospectus filed with the SEC on 21 May 2019; shares registered for exchange trading on 17 May 2019. The blank-check company later merged with the business that carries the name today.
  5. 2021
  6. ✎
    Renamed Celularity Inc
    Formerly GX Acquisition Corp..
  7. 2024
  8. 💰
    Record revenue of $54 million
    FY2024, the highest of the 6 years on record.

Events of Celularity Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$153 M$307 M$460 M$613 M2023202420252026

World rank over time

▼ down 10,754 places since 2022
2022-01-07: #12603#12,60320222022-12-25: #18998#18,99820222023-07-30: #23401#23,40120232024-01-05: #24360#24,36020242026-03-08: #11415#11,41520262026-08-01: #21784#21,78420262026-10-14: #21637#21,63720262026-10-30: #23357#23,3572026

Rank in USA: #3,102 (Jan 2022) · #3,845 (Dec 2022) · #4,500 (Jul 2023) · #4,005 (Jan 2024) · #2,219 (Mar 2026) · #3,948 (Aug 2026) · #3,878 (Oct 2026) · #4,064 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.5×
Price / book
—
Free cash flow yield
-23.8%
Net margin (TTM)
-245.8%
Operating margin
-230.9%
Return on equity
—
Liabilities / assets
135.5%
Revenue growth
-51.0%
R&D / revenue
56.6%
Revenue per employee
$92 K
Profit per employee
$-318 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $6M—FY19Fiscal year ending Dec 2020: revenue $14M, net income $-208M$14MFY20Fiscal year ending Dec 2021: revenue $21M, net income $-100M$21MFY21Fiscal year ending Dec 2022: revenue $18M, net income $14M$18MFY22Fiscal year ending Dec 2023: revenue $23M, net income $-196M$23MFY23Fiscal year ending Dec 2024: revenue $54M, net income $-58M$54MFY24Fiscal year ending Dec 2025: revenue $27M, net income $-92M$27MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$27M-51.0%$-61M$-92M-345.5%
Dec 2024$54M+138.1%$-38M$-58M-106.8%
Dec 2023$23M+26.6%$-192M$-196M-862.1%
Dec 2022$18M-15.7%$-26M$14M78.9%
Dec 2021$21M+49.4%$-109M$-100M-469.2%
Dec 2020$14M—$-152M$-208M-1458.2%
Dec 2019——$-2M$6M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-13M——$-3.59—
Dec 2024$-6M$0M$-7M$-2.64—
Dec 2023$-39M$1M$-40M$-11.02—
Dec 2022$-138M$5M$-143M$0.95—
Dec 2021$-110M$6M$-116M$-1.49—
Dec 2020$-63M$28M$-91M$-11.31—
Dec 2019$-1M——$0.10—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$19M
Net income, trailing 12 months
$-46M
RevenueNet income
Three months to Sep 2024: revenue $9M, net income $-16M$9MSep ’24Three months to Dec 2024 (from the annual report): revenue $18M, net income $-13M$18MDec ’24Three months to Mar 2025: revenue $11M, net income $-20M$11MMar ’25Three months to Jun 2025: revenue $6M, net income $-25M$6MJun ’25Three months to Sep 2025: revenue $5M, net income $-23M$5MSep ’25Three months to Dec 2025 (from the annual report): revenue $4M, net income $-24M$4MDec ’25Three months to Mar 2026: revenue $4M, net income $1M$4MMar ’26Three months to Jun 2026: revenue $5M, net income $1M$5MJun ’26

Latest quarter to Jun 2026: revenue $5M (-5.4% on a year earlier), net income $1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Celularity Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$27 M
Operating income
$-61 M
Net income
$-92 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$107 M
Total liabilities
$145 M
Total equity
$-38 M

As of December-2025

Top 33 institutional investors in Celularity Inc.#

As of Sep 30, 2026
33 institutions held 2.1 M shares (about 6.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 6.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Celularity Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1C V Starr & Co Inc764,0690 (0.00%)2.35%$1 MNov 10, 2026
2Vanguard Capital Management LLC646,444+25,339 (+4.08%)1.99%$1 MNov 13, 2026
3Geode Capital Management, LLC167,1500 (0.00%)0.52%$0 MNov 6, 2026
4Vanguard Fiduciary Trust Co121,516+41,642 (+52.13%)0.37%$0 MNov 13, 2026
5UBS Group AG80,075+78,395 (+4666.37%)0.25%$0 MNov 10, 2026
6BlackRock, Inc.76,3590 (0.00%)0.24%$0 MNov 13, 2026
7State Street Corp57,8300 (0.00%)0.18%$0 MNov 12, 2026
8Northern Trust Corp49,874+5,711 (+12.93%)0.15%$0 MNov 16, 2026
9Biltmore Family Office, LLC35,0000 (0.00%)0.11%$0 MNov 3, 2026
10HB Wealth Management, LLC31,9150 (0.00%)0.10%$0 MOct 23, 2026
11Sky Investment Group LLC29,920New0.09%$0 MOct 30, 2026
12Royal Bank Of Canada18,0000 (0.00%)0.06%$0 MNov 16, 2026
13Jane Street Group, LLC17,403-11,310 (-39.39%)0.05%$0 MNov 12, 2026
14IPG Investment Advisors LLC17,1690 (0.00%)0.05%$0 MOct 30, 2026
15Mercer Global Advisors Inc /adv15,200New0.05%$0 MNov 16, 2026
16BFC Planning, Inc.7,7130 (0.00%)0.02%$0 MNov 13, 2026
17Tower Research Capital LLC (TRC)3,323-1,788 (-34.98%)0.01%$0 MNov 16, 2026
18Wells Fargo & Company/mn2,5000 (0.00%)0.01%$0 MNov 16, 2026
19Vanguard Global Advisers, LLC2,3150 (0.00%)0.01%$0 MNov 13, 2026
20SBI Securities Co., Ltd.1,882-402 (-17.60%)0.01%$0 MOct 22, 2026
21Caldwell Sutter Capital, Inc.1,0000 (0.00%)0.00%$0 MNov 9, 2026
22CoreCap Advisors, LLC5000 (0.00%)0.00%$0 MOct 8, 2026
23HighMark Wealth Management LLC4410 (0.00%)0.00%$0 MNov 17, 2026
24Global Retirement Partners, LLC3000 (0.00%)0.00%$0 MNov 10, 2026
25Financial Perspectives, Inc1710 (0.00%)0.00%$0 MNov 3, 2026
Show all 33: investors 26 to 33
Institutional investors 26 to 33 in Celularity Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Valley National Advisers Inc1000 (0.00%)0.00%$0 MOct 23, 2026
27BNP Paribas Financial Markets990 (0.00%)0.00%$0 MNov 12, 2026
28Jones Financial Companies Lllp820 (0.00%)0.00%$0 MNov 13, 2026
29United Financial Planning Group LLC190 (0.00%)0.00%$0 MNov 4, 2026
30Jpmorgan Chase & Co160 (0.00%)0.00%$0 MNov 12, 2026
31Harbour Investments, Inc.150 (0.00%)0.00%$0 MNov 9, 2026
32Barclays PLC4New0.00%$0 MNov 6, 2026
33Danske Bank A/s10 (0.00%)0.00%$0 MNov 9, 2026

Mutual funds holding Celularity Inc.#

6 funds hold shares worth $1 M (about 2.4% of the company). Since their previous reports 2 added shares and 2 sold, selling $0 M net.
Mutual funds holding Celularity Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.455,049$0 M1.4%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC104,816$0 M0.32%<0.01%+22%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.166,056$0 M0.51%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC21,176$0 M0.07%<0.01%+6.7%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC20,677$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC8,438$0 M0.03%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Celularity Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
25
since
Celularity Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Stephen BrigidoPres., Functional RegenerationOption exercise+821——9,742Form 4
filed Robert J. HaririChief Executive Officer, DirectorOption exercise+3,281——2.85 MForm 4
filed John R. HainesSenior Exec Vice PresidentOption exercise+1,641——30,762Form 4
filed Robert J. HaririChief Executive Officer, DirectorShares withheld for tax-1,182$1.280$2 K2.85 MForm 4
filed Stephen BrigidoPres., Functional RegenerationShares withheld for tax-268$1.280$3439,474Form 4
filed John R. HainesSenior Exec Vice PresidentShares withheld for tax-583$1.280$74630,179Form 4
filed Geoffrey LingDirectorGrant or awardamended+19,231——256,026Form 4/A
filed Vincent LeVienDirectorGrant or awardamended+28,847——153,847Form 4/A

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Celularity Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
534,811
1.9% of shares · 2.33 days to cover
Buybacks, Q4 2020
$0M
Q4 2021
Shares sold short, last 24 reportsAll stocks →
Celularity Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2020Q4 2021$0M

Trading halts

  • 2024-11-15 14:56 UTC, code LUDP, resumed 15:01 UTC
  • 2024-11-14 20:25 UTC, code LUDP, resumed 20:30 UTC

Fails to deliver

  • : 4,254 shares at $0.85
  • : 6,254 shares at $0.94
  • : 406 shares at $0.79
  • : 74,477 shares at $0.75
  • : 54,289 shares at $0.98

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Celularity Inc. scorecard#

Passes 4 of the 19 checks that could be worked out: strongest in growth (3 of 6), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median1.5×Price to sales 1.5× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-23.8%Free cash flow is -23.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 6
    • ✗Revenue grew in the newest year-51.0%Revenue down 51.0% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years13.9%13.9% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median13.9%13.9% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-3.59 vs -2.64Diluted EPS -3.59 in fiscal 2025 against -2.64 the year before (report's currency).
    • ✓Net income higher than five years earlier-$92 M-$92 M in fiscal 2025 against -$208 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$92 MNet income -$92 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-230.9%-230.9% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-230.9%-230.9% in fiscal 2025 against -142.4% in 2022.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.15 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-15.22Z-score -15.22 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year16.9%Diluted shares up 16.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Celularity Inc.'s statements, beside the median of Biotechnology.

Celularity Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-230.9%-60.5%
Net margin-345.5%-68.9%
Revenue growth, 3 years a year13.9%12.9%
Revenue growth-51.0%15.8%

1of 8on the Piotroski tests of financial strength

  • Revenue fell 51.0% against the year before.
  • Net loss of $92 million, the 3th loss-making year in a row.
  • The share count rose 16.9% in the year.
  • Shareholders' equity is negative: -$38 million.

Celularity Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Celularity Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue275423182114—
Cost of revenue201516————
Gross profit——6.8−1.7129.3—
Research and development151730788853—
Selling, general and administrative515951667131—
Operating income−61−38−192−26−109−152r−1.7r
Interest and finance income—————1.83.8
Other non-operating income (expense)−30−20−4.0409.0−61r8.2r
Income before tax−92−58−19614−100−213r6.5r
Income tax0.0—0.00.00.0−4.7r0.7
Income from continuing operations−61−38−192−26−109−152—
Net income including minority interests——−19614−100−208—
Net income attributable to shareholders−92−58−19614−100−208r5.9r
Earnings per share, basic-3.59-2.64-11.021.01r-1.49-11.31r0.10r
Earnings per share, diluted-3.59-2.64-11.020.95r-1.49-11.31r0.10r
Shares, weighted average (basic)26221814r67——
Shares, weighted average (diluted)26221815r6718r26r
Balance sheet
Cash and cash equivalents6.20.70.2143754r0.9
Receivables4.7——————
Inventory0.65.45.85.39.59.5r—
Other current assets0.90.91.77.30.00.9—
Current assets122120345972r1.0
Property, plant and equipment566268769190—
Right-of-use (leased) assets11111113———
Goodwill7.37.37.3120123123127
Other intangible assets7.89.211121123125—
Total assets107133144401414431r292
Accounts payable2623145.89.35.4r0.2
Debt due within a year——39————
Current liabilities815467622627r0.2
Long-term debt34——————
Lease liabilities (non-current)27272628———
Total liabilities145124103202315412r28r
Retained earnings−991−900−842−645−664−564r3.9r
Shareholders' equity−388.84119999−531r−327r
Total equity——4119999−531r5.0
Total liabilities and equity107133144401414431r292
Shares outstanding29231915r124193.2
Cash-flow statement
Depreciation and amortization7.37.99.39.48.88.2—
Share-based compensation11120r16404.4—
Cash from operating activities−13−6.4−39−138−110−63r−1.1
Capital expenditure—−0.2−1.0−5.2−6.2−28—
Cash from investing activities—0.5−4.0−5.2−5.9−13r−287
Shares issued1.0——————
Shares bought back—————−0.3—
Cash from financing activities196.72412099102289
Change in cash5.40.8−19−23−1726r0.9
Report10-K10-K10-K10-K10-K10-K10-K/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Celularity Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$13 M50%
  • License Royalty and Other$8 M30%
  • Service(total)$5 M20%

Business segments

  • Degenerative Disease$17 M65%
  • Biobanking$5 M20%
  • Cell Therapy$4 M14%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Celularity Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 11 · Material agreement 12 · New debt 6 · Unregistered share sale 6 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1

Celularity Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officersMaterial agreementNew debtUnregistered share sale8-K
Directors and officers8-K
Delisting notice8-K
Directors and officersMaterial agreementNew debt8-K
Directors and officers8-K
Delisting notice8-K
Directors and officers8-K
Material agreementNew debt8-K
Directors and officersMaterial agreementNew debtShareholder rights changed8-K
Material agreement8-K
Directors and officers8-K
Directors and officers8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder vote8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Material agreement8-K
Material agreement8-K
Material agreementNew debtUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 29, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Celularity Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$2 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Jul 2025$2 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Jul 2025$1 MPrivate placement after listingUnder $2 million14equity, optionsSEC
Jul 2025$7 MPrivate placement after listing$2 to $10 million1debt, optionsSEC
May 2022$30 MPrivate placement after listing$10 to $50 million1equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Celularity Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2023, most often on health issues.

Lobbying, 2023
$20 K
#1,337 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2023
2026 so far
—
  • Health Issues2 reports

Lobbying firms hired in 2023

DA VINCI GROUP $20 K

Celularity Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2023$20 K—2
2022$40 K—4
2021$30 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Celularity, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Celularity Inc. compares in Biotechnology

  • Market cap$28 M · higher than 20% of 726
  • Revenue$27 M · higher than 52% of 647
  • Net margin-245.8% · higher than 23% of 408
  • Revenue growth-51.0% · higher than 18% of 438
  • Price / sales1.5× · lower than 91% of 339
  • FCF yield-23.8% · higher than 40% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Celularity Inc.🇺🇸$28 M—-245.8%-51.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on July 2022
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Celularity Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Celularity Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Celularity Inc.? Suggest a correction